622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

• C Daniel De Magalhaes Filho,
• Chung-Wein Lee,
• Nikolai Suslov,
• Jerry Fong,
• Miguel Garcia-Guzman

Affiliations

C Daniel De Magalhaes Filho

Rakuten Medical, San Diego, CA, USA

Chung-Wein Lee

Rakuten Medical, San Diego, CA, USA

Nikolai Suslov

Rakuten Medical, San Diego, CA, USA

Jerry Fong

Rakuten Medical, San Diego, CA, USA

Miguel Garcia-Guzman

Rakuten Medical, San Diego, CA, USA